SEHK:6855Biotechs
Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation
Ascentage Pharma Group International (SEHK:6855) drew fresh market attention after presenting new ASCO 2026 data on olverembatinib in chronic myeloid leukemia and first clinical results for alrizomadlin in pediatric sarcomas.
See our latest analysis for Ascentage Pharma Group International.
The ASCO 2026 updates arrived as the stock posted a 3.93% 1 day share price gain to HK$34.9. That move sits against a year to date share price decline of 31.43% and a 1 year total shareholder return that...